A20/TNFAIP3 Recombinant Rabbit mAb (S-2578-5)

A20/TNFAIP3 is a 790-residue cytoplasmic zinc-finger deubiquitinase and E3 ubiquitin ligase whose dual enzymatic activities act as a pivotal negative feedback brake on NF-κB, IRF3, RIPK1 and NLRP3 inflammasome signaling by cleaving K63-linked polyubiquitin chains from adaptor proteins such as TRAF6, NEMO and RIPK2 while simultaneously assembling K48-linked ubiquitin onto these same targets to promote their proteasomal degradation, thereby preventing excessive inflammatory cytokine, type-I interferon and cell death responses; its expression is rapidly up-regulated by NF-κB itself and by type-I interferons, creating an autoregulatory loop that is indispensable for immune homeostasis, because germline loss-of-function variants cause auto-inflammatory or autoimmune disorders in humans—such as haploinsufficiency leading to Behçet-like disease, psoriasis or systemic lupus erythematosus—whereas somatic inactivation is frequently observed in B-cell lymphomas, promoting malignant survival, making A20/TNFAIP3 both a critical rheostat of innate immunity and a tumor suppressor whose manipulation is a promising therapeutic target in chronic inflammation and cancer.